


In the early 2000s, HMS scientists discovered that blocking the PD-1/PD-L1 pathway – a mechanism that some cancers use to evade the immune system could enable the immune system to fight these cancers.



The first drug blocking this pathway, a form of cancer immunotherapy, was approved in 2014.



Today, these therapies are approved for more than 25 cancer types and have extended the lives of millions of patients.





Protect Research at Harvard Medical School

hms.harvard.edu/protect-research